Stockscreener 앱 받기
189.55
3.51%
6.42
전일 마감가:
$183.13
열려 있는:
$183.3
하루 거래량:
284.90K
Relative Volume:
1.36
시가총액:
$3.73B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
75.52
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
+2.53%
1개월 성능:
-7.81%
6개월 성능:
+65.62%
1년 성능:
+66.99%
1일 변동 폭
$181.68
$190.28
1주일 범위
$179.65
$192.44
52주 변동 폭
$93.58
$212.49
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
189.55 | 3.60B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Citigroup | Buy |
| 2025-04-10 | 개시 | Stifel | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
Market Leaders: Is Ligand Pharmaceuticals Incorporated stock safe for conservative investorsPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - moha.gov.vn
Stifel Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Buy Recommendation - Nasdaq
RBC Capital Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Outperform Recommendation - Nasdaq
RBC Capital Maintains Ligand Pharmaceuticals (LGND) Outperform Recommendation - Nasdaq
Benchmark reaffirms Buy rating on Ligand Pharma stock with $220 target - Investing.com Canada
Oppenheimer reiterates Outperform rating on Ligand Pharma stock at $275 By Investing.com - Investing.com Canada
LGND: RBC Capital Raises Price Target, Maintains 'Outperform' Ra - GuruFocus
LGND: Stifel Raises Price Target to $230, Maintains 'Buy' Rating - GuruFocus
Stifel Nicolaus Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $230.00 - MarketBeat
RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating - marketscreener.com
Ligand Pharma stock price target raised to $230 by Stifel on growth outlook - Investing.com Canada
Ligand Pharmaceuticals IncIntroduces 2026 - 富途牛牛
Citigroup Initiates Coverage On LGND with a Buy Rating | LGND St - GuruFocus
Major Decision: Jason Aryeh Exercises Options, Realizing $234K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2026 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Coverage Initiated by Analysts at Citigroup - MarketBeat
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance - Quiver Quantitative
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2026 - marketscreener.com
Ligand (LGND) Highlights Strategic Advances and Growth Prospects at Investor Day - GuruFocus
(LGND) Ligand Pharmaceuticals Expects Full Year 2025 Core Revenue Range $225M to $235M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects Full Year 2026 Revenue Range $245M to $285M, vs. FactSet Est of $259.2M - marketscreener.com
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook - Quiver Quantitative
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - Yahoo Finance
Is Ligand Pharmaceuticals Incorporated LGDN a good long term investmentGlobal Trade Effects & Demo Trading Rooms Open Daily - earlytimes.in
Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Price Target Increased by 25.41% to 0.00 - Nasdaq
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $91,457.28 in Stock - MarketBeat
Why analysts upgrade Ligand Pharmaceuticals Incorporated stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - Newser
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% - GlobeNewswire Inc.
Can Ligand Pharmaceuticals Incorporated stock double in next 5 yearsInsider Selling & Weekly Chart Analysis and Guides - Newser
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
A Look Into Ligand Pharmaceuticals Inc's Price Over Earnings - Benzinga
Ligand Pharmaceuticals Incorporated $LGND Stake Decreased by Prudential Financial Inc. - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Granite Investment Partners LLC - MarketBeat
Will Ligand Pharmaceuticals Incorporated (LGDN) stock hit analyst forecastsWeekly Market Outlook & Stock Portfolio Risk Control - Newser
Will Ligand Pharmaceuticals Incorporated stock benefit from sector rotationTreasury Yields & Real-Time Volume Triggers - Newser
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by Russell Investments Group Ltd. - MarketBeat
Is Ligand Pharmaceuticals Incorporated (LGDN) stock at risk of policy regulationBreakout Watch & AI Based Buy/Sell Signal Reports - Newser
How strong is Ligand Pharmaceuticals Incorporated (LGDN) stock earnings growth - Newser
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals (LGND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by SG Americas Securities LLC - MarketBeat
Advantage Alpha Capital Partners LP Purchases New Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Portfolio Recap: Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025 - moha.gov.vn
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest - Benzinga
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Volatility Report & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know - AOL.com
Ligand Pharmaceuticals Incorporated $LGND Stake Boosted by Geode Capital Management LLC - MarketBeat
Ligand Pharma stock maintains Outperform rating at RBC ahead of Investor Day By Investing.com - Investing.com Canada
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):